Class I
Class I encompasses infection prevention and wound‑management technologies tailored to military medicine: rapid point‑of‑care diagnostics, antimicrobial materials and coatings, biofilm‑targeting therapies, and portable sterilization/decontamination systems that reduce sepsis, antimicrobial resistance, and evacuation burden.
Technical Challenges
Rapid identification of polymicrobial infections and resistant organisms at point of injury.
Effective prevention and disruption of biofilms on wounds, implants, and indwelling devices.
Robust, lightweight sterilization and decontamination suitable for austere, power‑limited environments.
Maintaining antimicrobial efficacy without promoting resistance or systemic toxicity in prolonged field care.
Emerging Opportunities
Validated, ruggedized point‑of‑care molecular and phenotypic diagnostics usable by non‑specialists.
Active wound dressings and delivery systems that control infection and support tissue regeneration in combat wounds.
Practical surface and device coatings that prevent colonization under battlefield conditions.
Scalable protocols and devices for rapid decontamination of personnel, equipment, and transport enclosures during outbreaks or CBRN events.
Current and Emerging Technologies in Class I
Rapid point‑of‑care diagnostics
Compact PCR, isothermal amplification, CRISPR‑based assays and rapid phenotypic susceptibility tests that identify pathogens and resistance markers within minutes to hours at the point of injury or in forward aid stations.
Antimicrobial materials and coatings
Silver, copper, peptide‑based and polymeric coatings for dressings, devices and surfaces that reduce colonization and biofilm formation while minimizing systemic exposure and resistance selection pressure.
Biofilm disruption and targeted antimicrobials
Enzymatic dispersal agents, antibiofilm small molecules, bacteriophage therapies and localized antimicrobial delivery that address persistent infections in polytrauma and implant‑associated wounds.
Portable sterilization and decontamination systems
Battery‑operated UV, vaporized hydrogen peroxide, advanced filtration and low‑resource autoclave technologies for rapid equipment, triage area and casualty decontamination in expeditionary settings.
Advanced wound dressings and regenerative scaffolds
Controlled‑release antibiotic dressings, hemostatic composites with antimicrobial function, and bioactive scaffolds that combine infection control with tissue repair for combat wounds.
Importance to Military Medicine
Improve combat casualty survival
Rapid infection control and accurate diagnostics reduce progression to sepsis and enable timely, targeted therapy after blast and penetrating injuries.
Enable prolonged and distributed care
Solutions that function without immediate evacuation preserve limb and life during delayed transport or prolonged field care scenarios.
Reduce evacuation and resource burden
On‑site diagnostics and effective local interventions limit medevac requirements and hospital resource utilization, improving operational readiness.
Mitigate antimicrobial resistance and infection complications
Targeted therapies and stewardship enabled by rapid testing reduce reliance on broad‑spectrum agents and lower long‑term AMR risk among deployed forces.
Alignment with the MTEC Mission
Supports DoD priorities for force health protection, combat casualty care, and technologies optimized for austere and expeditionary environments.
Accelerates translation of dual‑use biomedical innovations from industry and academia into field‑ready solutions, consistent with MTEC’s mission.
Enables collaborative, multidisciplinary projects spanning diagnostics, materials science, microbiology and clinical trauma care.
Delivers measurable impact on readiness by reducing infection‑related morbidity and preserving deployable medical capability.
Dual-Use (Military + Civilian) Applications
Hospital and civilian trauma centers benefit from rugged point‑of‑care diagnostics and advanced dressings developed for combat wounds.
Outbreak response and public health use portable decontamination systems and rapid assays originally designed for deployed settings.
Civilian EMS and disaster medicine adopt lightweight sterilization and field‑usable infection control technologies to improve surge capacity.
Commercialization pathways enable dual‑use scaling, regulatory approval and wider public health impact while meeting military specifications.
Explore MTEC Members with Class I Capabilities
MTEC members bring multidisciplinary strengths—bioengineering, microbiology, clinical trauma expertise, and device commercialization experience—needed to mature Class I solutions from concept to field use.
Members provide access to preclinical models, human factors testing, regulatory strategy and partnerships with DoD clinical sites to validate performance under operational constraints.
Explore member profiles to identify collaborators with capabilities in diagnostics, antimicrobial materials, wound healing, and field‑usable sterilization—partners ready to accelerate Class I technologies into practice.
49 Members with Class I capabilities.
Humanetics Corporation is a clinical-stage pharmaceutical company based in Minneapolis, Minnesota, focused on developing and commercializing products to enhance human health and wellbeing. Founded in 1988, the company specializes in radiation modulators, adjunctive oncology therapies, and pulmonary protective therapies, particularly for COVID-19. Humanetics is known for its lead drug candidate, BIO 300, which is being developed as a radioprotectant for military and civilian use, as well as a treatment to improve outcomes in cancer patients receiving radiotherapy. The company is actively engaged in research programs for non-small cell lung cancer, prostate cancer, and head and neck cancers.
Altra Inc. is at the forefront of revolutionizing infusion therapy with its innovative Altra Infusion System. The company is dedicated to addressing the critical challenges in the infusion industry, such as mechanical failures, flow issues, and false alarms, which contribute to a significant portion of medication errors and adverse drug events. Altra's mission is to ensure patient safety and improve healthcare delivery through advanced technology solutions.
Action Medical Technologies is a pharmaceutical and medical device company focused on developing innovative solutions that integrate medications with advanced devices and injector systems to improve patient outcomes, particularly in austere prehospital environments.
Bessel helps medtech startups and scaling teams move faster with hands-on support across R&D, marketing, quality, regulatory readiness, product development, manufacturing transfer, commercialization, fundraising readiness, and high-performance team execution. From Rapid Innovation to Breakthrough Impact, Bessel helps startups and commercially scaling teams build better and deliver faster with Bessel's AI Teammate for high-performance blended human + AI teams. Experience Bessel Rapid Innovation: We embed with your team to rescue stalled projects or fill critical gaps. From R&D to Quality Systems to Regulatory Affairs, we drive rapid progress to reduce your burn rate and improve profitability. We help your team deliver measurable results: reduced COGS, decreased complaints, improved performance. Our Powered by Bessel™ Accelerator is an Intensive, fixed-duration program to refine your technology strategy, align teams, and prepare for fundraising—perfect for startups seeking clarity and velocity. Save months in development, find your sweet spot with investors, build and support your team. The Bessel Origin™ workforce development program, born in the classroom, trains emerging medtech teams in design thinking and agile teamwork, fueling innovation. Boost team performance and identify, develop, and retain your emerging leaders.
Harmac is a global contract design and manufacturing organization specializing in single-use medical devices. With over four decades of experience, Harmac provides comprehensive services including product design and development, advanced manufacturing, automation, value engineering, quality assurance, and packaging and sterilization. The company is known for its operational excellence, regulatory compliance, and commitment to sustainability and community engagement. Harmac operates facilities across the United States, Ireland, and Mexico, supporting customers worldwide and across a range of clinical applications. ISO 13485 Certified and FDA Registered.
PinMed, Inc., is a National Innovation Award-winning bioinformatics/medical-device company that develops high-fidelity cardiovascular monitoring systems, personalized (adaptive) software, and integrated systems and custom solutions for tracking cardiovascular data in the most challenging environments (e.g., intensive activity, extreme electromagnetic interference, and interventional cardiovascular procedures) and identifying subtle but clinically important indicators of cardiovascular events. PinMed’s award-winning solutions include versatile, multisensor, high-fidelity monitoring systems for various hospital and ambulatory settings. The company has extensive experience in electronic and mechanical engineering, development of software and firmware for various processors, computational modeling, and cardiovascular physiology. PinMed’s flagship mobile platform, PELEX, provides unparalleled versatility in physiological monitoring and has been cleared by the FDA for diagnostic 12-lead ECG testing and various types of ambulatory monitoring.
Evimero is an interdisciplinary company focused on understanding the interactions between microorganisms and human health, agriculture, and the environment, utilizing Systems Biology and AI/ML. Evimero applies molecular principles to infectious disease and microbiome science to improve health outcomes and environmental sustainability through targeted interventions in dysbiotic microbiomes and in people with infectious disorders. Evimero has an infectious disease product pipeline including both prophylactic and diagnostic assets against common causes of Travelers' Diarrhea, including a unique approach to preventing infection with human Norovirus, enterotoxigenic E. coli (ETEC) and others. Evimero's pipeline of drugs targeting human and animal microbiomes includes early-stage assets aimed at generalized microbiome-driven inflammation and gut leak, and specific disease-targeted disorders including Parkinson Disease and Inflammatory Bowel Diseases. Evimero's platform also makes possible a suite of point-of-care diagnostics that can be used for patient cohorting (infectious diseases), risk stratification, and ultimately informing therapeutic decision-making. The nature of Evimero's platform assures a steady stream of novel assets targeting both infectious diseases and chronic disorders with roots in microbiome dysfunction.
Ease Healthcare (a registered DBA of MPS Medical, Inc.) is committed to advancing next-generation military medicine by accelerating access to clinically validated diagnostic tools, monitoring devices, and health and wellness technologies. As a trusted commercialization partner and distributor, the company empowers providers, organizations, and individuals with advanced solutions that support early detection, timely intervention, and improved health outcomes in both civilian and military settings. With a mission to make cutting-edge science and technology accessible to all, Ease Healthcare focuses on addressing critical health challenges such as 02 delivery, cancer, and cardiovascular disease —areas that directly impact force readiness and resilience. The company’s vision is to break barriers in healthcare by delivering innovative medical solutions that are affordable, accessible, and simple to use, regardless of economic or geographic limitations. In addition to bringing transformative technologies to market, Ease Healthcare provides turnkey services for medical device manufacturing and distribution, guiding partners from product development through regulatory compliance and successful deployment. By combining technical expertise with a dedication to accessibility, Ease Healthcare supports the Department of Defense’s priorities in preparing and protecting service members with next-generation healthcare solutions.
Exponent is a multidisciplinary science and engineering consulting firm serving sectors including healthcare, energy, manufacturing, and consumer products. From medical devices, pharmaceuticals, and supplements to digital health and wearables, we deliver rigorous science that quantifies impacts on human health. Exponent helps you push the envelope on the development, deployment, safety, and effectiveness of cutting-edge drugs, devices, and diagnostics — concomitantly balancing benefits and risks. Count on our multidisciplinary, data-driven, evidence-based assessments to give you clarity on your most complex product needs and challenges. With lives on the line, innovations that support healthcare demand the highest levels of scientific rigor. Whether you’re developing a novel drug, a sturdier stent, or a faster flu test, you need clear answers to complex questions, quickly. Exponent supports our life sciences clients across the total product lifecycle by solving critical design, regulatory, safety, and market access challenges. We can collaborate with you throughout your journey, helping you navigate risks and opportunities — and optimize outcomes — with science-based strategies and specialized expertise.
Purgo Scientific is a medical device company dedicated to developing effective solutions for the biofilm infections crisis in orthopedic surgery. Their mission is to provide a locally targeted sustained delivery device that ensures the right therapy is delivered to the right place for the right duration, ultimately improving patient outcomes and reducing the impact of surgical site infections.
PPD, a clinical research business of Thermo Fisher Scientific, is a leading provider of global contract research organization (CRO) solutions. The company is dedicated to helping clients accelerate the development of life-changing therapies through comprehensive drug development, laboratory, and lifecycle services. With a commitment to operational excellence and innovative technology, PPD empowers its customers to bring therapies to market faster and improve patient health. PPD has been recognized as an industry leader in clinical development digital transformation services and patient engagement digital transformation. With over 30 years of clinical leadership and a workforce of more than 30,000 employees globally, PPD has conducted over 2,100 trials in the past five years.
Simbex is a leading partner in medical device and consumer health product design and development, recognized for transforming complex ideas into commercially successful solutions. With a multidisciplinary team, Simbex excels in engineering, product design, software, data analytics, and commercialization strategy, supporting innovators from concept to market. Their mission is to deliver impactful medical devices and consumer health products that improve health outcomes and quality of life. Simbex is known for its holistic approach, deep regulatory expertise, and commitment to innovation and excellence in the health technology sector. The company is also active in thought leadership, regularly publishing regulatory and reimbursement updates, and hosting educational webinars for the MedTech community. Simbex maintains a robust Quality Management System compliant with ISO 13485 and FDA 21 CFR 820, ensuring high standards in product development. The company is also committed to supporting diversity in MedTech, including initiatives for women in the sector. Simbex's leadership and advisory team bring decades of experience in biomedical engineering, commercialization, regulatory affairs, and technology innovation, further strengthening its position as a trusted partner in the MedTech ecosystem.
Prolucid Technologies Inc. specializes in custom software development for highly regulated industries, including medical and nuclear sectors. With over 17 years of experience and more than 1200 projects completed, Prolucid delivers robust, secure, and compliant software solutions. The company is ISO 13485 certified for medical software and adheres to CSA N299.1 and ISO 9001 standards for nuclear applications. Prolucid offers end-to-end services from project definition and planning to design, development, verification, and ongoing support, leveraging advanced technologies such as AI, ML, computer vision, and cloud infrastructure.
FreMon Scientific develops biomedical platforms focused on dry, electronically controlled thawing of blood, plasma, and cell therapy products. Its core solutions include portable thawing devices and disposable thermal sleeves for optimized, contamination-reduced, and traceable thawing workflows. The systems are validated for regulatory compliance, supported by clinical studies, and utilized in hospitals, laboratories, and production settings globally.
Profusa, Inc. is a pioneering digital health company based in the San Francisco Bay Area, dedicated to making the body’s chemistry easily accessible to improve health and wellness. Profusa develops tissue-integrating biosensors for continuous, real-time monitoring of body chemistries, empowering individuals and clinicians with actionable, medical-grade data to transform personal health management and disease prevention. Their unique bioengineering approach overcomes the foreign body response, enabling long-term, in-body monitoring through tiny, flexible biosensors that become one with the body. Profusa’s technology platform supports both consumer and medical applications, with a vision to revolutionize personalized medicine and digital health. The company is supported by significant grant funding from agencies such as DARPA and NIH, and collaborates with leading academic, hospital, and industry partners worldwide.

Safi Biotherapeutics
Next-Generation Manufactured Red Blood Cells for Extended Battlefield Blood Supply: Safi Biotherapeutics
Safi Biotherapeutics is developing manufactured red blood cells (mRBCs) with extended shelf life to improve battlefield transfusion readiness and emergency trauma care.
Non-Invasive Glymphatic (GF) Monitoring and Recovery Optimization for Warfighter Cognitive Readiness
Applied Cognition is developing non-invasive glymphatic monitoring and recovery technologies to enhance warfighter cognitive readiness, resilience, and sleep recovery.
Moberg Analytics
Moberg Analytics – Advanced Brain Monitoring & Critical Care Informatic
Moberg’s platform unifies brain monitoring data for faster, precise treatment of severe brain injuries in military and civilian care.
University of California San Francisco
TemPredict: AI-Driven Wearable Monitoring for Early Illness Detection and Warfighter Readiness
TemPredict: AI wearables detect early illness and health risks to support warfighter readiness.